NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) have each recommended that stockholders vote “FOR” the previously announced acquisition of the Company by RadNet, Inc. (“RadNet”) at the Company’s upcoming Special Meeting of Stockholder ...

NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Prof ...

Financial Data and Key Metrics Changes - For Q1 2025, RadNet reported total revenue of $471.4 million, an increase of $39.7 million or 9.2% compared to Q1 2024. Adjusted EBITDA was $46.4 million, a decrease of $12.1 million or 20.6% year-over-year [21][22] - Adjusting for the estimated $22 million impact from severe weather and wildfires, revenue would have increased by 14.3% year-over-year. Adjusted EBITDA, accounting for a $15 million impact, would have increased by 5% [22] - The company ended Q1 2025 with a cash balance of $717 million and a net debt to adjusted EBITDA ratio of slightly more than one [17][24] Business Line Data and Key Metrics Changes - The Digital Health segment reported revenue of $19.2 million, a 31.1% increase year-over-year, with adjusted EBITDA of $3.7 million, up 5.4% [22][23] - AI revenue within Digital Health grew by 33.3%, driven by improved adoption of the EBCD program [23] - PET CT volumes increased by 22.9%, attributed to the growth of newer prostate and brain procedures [8] Market Data and Key Metrics Changes - The company experienced a gradual shift towards advanced imaging, with 26.9% of procedural volume coming from advanced imaging in Q1 2025, compared to 25.7% in Q1 2024 [7] - The adoption rate of the EBCD program reached over 40% nationally, indicating strong market acceptance [12] Company Strategy and Development Direction - RadNet is focused on expanding its digital health initiatives, including the TechLive remote technologist solution and the EBCD AI-powered breast cancer screening program [10][12] - The company announced the acquisition of iCAD Inc, aiming to enhance its AI-powered breast health solutions and expand its market presence [14][15] - RadNet plans to open 11 new centers by the end of 2025 and has a robust pipeline for joint ventures and acquisitions [16][18] Management's Comments on Operating Environment and Future Outlook - Management noted that the severe weather conditions in early 2025 negatively impacted performance but expressed confidence in recovery and strong growth trends in subsequent months [6][9] - The company anticipates continued growth in advanced imaging and routine imaging, driven by technological advancements and increased demand [41][43] - Management expects to see improved margins due to the growth of advanced imaging and the implementation of AI tools [75] Other Important Information - The company has an active pipeline of acquisitions and is evaluating opportunities to advance its strategic objectives [18] - RadNet's liquidity position remains strong, with full availability of a $282 million revolving credit facility [23] Q&A Session Summary Question: What is the outlook for growth in advanced imaging over the next few years? - Management expects growth in advanced imaging to continue, driven by AI tools and new equipment investments [39][41] Question: Can you provide insights on the M&A pipeline? - The pipeline is robust, with ongoing discussions with hospitals recognizing the value of RadNet's radiology solutions [44][46] Question: What are the trends in technologist hiring? - There are improvements in hiring trends, and the company remains comfortable with the projected $45 million increase in labor costs [52][58] Question: How did revenue perform against internal expectations? - Revenue was strong and aligned with internal guidance, with a bounce back in March after weather-related impacts [66][67] Question: What is driving the expected increase in EBITDA margins? - Growth in advanced imaging and the implementation of AI programs are primary drivers for improved margins [75] Question: What is the status of stock-based compensation? - The increase in stock-based compensation is due to vesting from past years and new hires, but it is expected to decrease in subsequent quarters [76]

For the quarter ended March 2025, Hologic (HOLX) reported revenue of $1.01 billion, down 1.2% over the same period last year. EPS came in at $1.03, compared to $1.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1 billion, representing a surprise of +0.34%. The company delivered an EPS surprise of +0.98%, with the consensus EPS estimate being $1.02.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectat ...

Hologic (HOLX) Q2 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Hologic's Second Quarter Fiscal twenty twenty five Earnings Conference Call. My name is Rachel, and I'm your operator for today's call. Today's conference is being recorded. All lines have been placed on mute. I would now like to introduce Mike Watts to begin the call. Speaker1 Thank you, Rachel. Good afternoon and thank you for joining Hologic's second quarter fiscal twenty twenty five earnings call. With ...

iCAD collaborates with Microsoft to offer radiology providers the option for automated patient reporting on mammography results through PowerScribe integration About iCAD, Inc. NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD's ProFound Breast Health Suite on Microsoft's Pr ...

Wall Street analysts forecast that Hologic (HOLX) will report quarterly earnings of $1.02 per share in its upcoming release, pointing to a year-over-year decline of 1%. It is anticipated that revenues will amount to $1 billion, exhibiting a decline of 1.6% compared to the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections duri ...

Core Viewpoint - RadNet, Inc. has announced a definitive merger agreement to acquire iCAD, Inc. in an all-stock transaction valued at approximately $103 million, representing a significant premium for iCAD stockholders [1][2]. Group 1: Merger Details - iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger, equating to about $3.61 per share on a fully diluted basis [2]. - The transaction is expected to close in the second or third quarter of 2025, pending approval from iCAD stockholders and other customary closing conditions [3]. Group 2: Strategic Rationale - The merger aims to enhance patient diagnosis and outcomes in breast cancer detection through the combined capabilities of iCAD's ProFound Breast Health Suite and RadNet's DeepHealth AI-powered solutions [3]. - The acquisition will expand RadNet's existing network, which includes over 1,500 healthcare provider locations and facilitates over 8 million annual mammograms across 50 countries [3][5]. Group 3: Leadership Comments - Dr. Howard Berger, CEO of RadNet, emphasized the potential to improve global breast cancer diagnosis and outcomes through this merger [3]. - Dana Brown, CEO of iCAD, highlighted the opportunity to redefine disease detection and treatment, aiming to enhance access to advanced tools and improve patient care [3]. Group 4: Future Plans - Following the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio, which is expected to accelerate growth and leadership in cancer screening and artificial intelligence [5]. - RadNet plans to host an investor conference call to discuss the transaction details, indicating a commitment to transparency and stakeholder engagement [4][5].